slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 15,541-15,570
Pages 619
Rows per page 30
Component
15,541-15,570 of 18,554
240
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
242
The slide uses direct quotes from a Key Opinion Leader (KOL) to build a case against the drug's safety and market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
247
The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
248
The slide uses a Q&A transcript format to highlight potential safety concerns and lack of transparency regarding trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
249
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
250
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
262
The slide uses emotional imagery and anecdotal evidence to undermine the credibility of a key figure in the PWS space.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
263
Includes a screenshot of a blog post and two photos of the doctor interacting with a child.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
264
The slide uses direct quotes and expert testimony to build a case against the credibility of a key opinion leader (Miller).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
266
Uses press release excerpts to establish a pattern of behavior or conflict of interest.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
267
The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionable association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
269
The slide uses direct quotes from an Anthem VP to undermine the product's market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
275
The slide uses direct quotes from a researcher to undermine the perceived positive sentiment of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
276
The slide uses a Q&A format to highlight the tension between corporate marketing pressure and scientific/ethical boundaries.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
277
The slide uses a Q&A format to highlight negative expert sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
278
The slide uses a Q&A format to highlight negative expert sentiment regarding commercial viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
281
The slide uses a 'villain/expert critique' format to undermine the target company's drug efficacy and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
282
The slide uses highlighted text to draw attention to key negative sentiments from the KOL.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
283
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
284
The slide uses a Q&A transcript format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletion when combined with diuretics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
289
Uses Q&A format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
296
The slide uses a Q&A transcript format to provide primary source evidence of a product flaw.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit